Medicis kept at outperform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Medicis Pharmaceutical Corp. at outperform, above average risk, with a $34 price target as IMS Health data shows Solodyn prescriptions continue to grow steadily. For the week ended Aug. 18, Solodyn total prescriptions are up 14% compared to the prior week. Oral acne prescriptions continue on pace above the analyst's estimates. The company's acne franchise is up 69% from the comparable week last year. RBC believes the peak potential for Solodyn is between $175 million and $250 million in annual gross sales. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up 56 cents, or 1.96%, at $29.18, on volume of 647,000 shares versus the three-month running average of 1,151,660 shares. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.